Click here to get full coverage on ANVS Stock Price and Chart — NYSE:ANVS - TradingView

ANVS Stock Price and Chart — NYSE:ANVS  TradingView

ANVS Stock Price and Chart — NYSE:ANVS - TradingView

Click here to get full coverage on Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan

Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market  Stock Titan

Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan

Click here to get full coverage on Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat

Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock  MarketBeat

Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat

Click here to get full coverage on ANVS Apr 2026 2.500 put (ANVS260402P00002500) stock historical prices and data - Yahoo Finance UK

ANVS Apr 2026 2.500 put (ANVS260402P00002500) stock historical prices and data  Yahoo Finance UK

ANVS Apr 2026 2.500 put (ANVS260402P00002500) stock historical prices and data - Yahoo Finance UK

Click here to get full coverage on Annovis Bio Stock (ANVS) Opinions on Phase 3 Alzheimer’s Trial Progress - quiverquant.com

Annovis Bio Stock (ANVS) Opinions on Phase 3 Alzheimer’s Trial Progress  quiverquant.com

Annovis Bio Stock (ANVS) Opinions on Phase 3 Alzheimer’s Trial Progress - quiverquant.com

Click here to get full coverage on Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections - ChartMill

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections  ChartMill

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections - ChartMill

Click here to get full coverage on [144] Annovis Bio, Inc. SEC Filing - Stock Titan

[144] Annovis Bio, Inc. SEC Filing  Stock Titan

[144] Annovis Bio, Inc. SEC Filing - Stock Titan

Click here to get full coverage on ANVS Apr 2026 1.000 call (ANVS260402C00001000) interactive stock chart - sg.finance.yahoo.com

ANVS Apr 2026 1.000 call (ANVS260402C00001000) interactive stock chart  sg.finance.yahoo.com

ANVS Apr 2026 1.000 call (ANVS260402C00001000) interactive stock chart - sg.finance.yahoo.com

Click here to get full coverage on $ANVS stock is up 13% today. Here's what we see in our data. - quiverquant.com

$ANVS stock is up 13% today. Here's what we see in our data.  quiverquant.com

$ANVS stock is up 13% today. Here's what we see in our data. - quiverquant.com

Click here to get full coverage on Annovis Publishes Historical Review of Buntanetap in The Scientist - TradingView

Annovis Publishes Historical Review of Buntanetap in The Scientist  TradingView

Annovis Publishes Historical Review of Buntanetap in The Scientist - TradingView

Click here to get full coverage on If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan

If You Invested $1,000 in Annovis Bio Inc (ANVS)  Stock Titan

If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan

Click here to get full coverage on $ANVS stock is up 4% today. Here's what we see in our data. - quiverquant.com

$ANVS stock is up 4% today. Here's what we see in our data.  quiverquant.com

$ANVS stock is up 4% today. Here's what we see in our data. - quiverquant.com

Click here to get full coverage on Annovis Bio Director Purchased Shares Worth Over $1.4M - TradingView

Annovis Bio Director Purchased Shares Worth Over $1.4M  TradingView

Annovis Bio Director Purchased Shares Worth Over $1.4M - TradingView

Click here to get full coverage on We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Yahoo Finance

We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully  Yahoo Finance

We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Yahoo Finance

Click here to get full coverage on New Alzheimer’s and Parkinson’s trial data from Annovis headed to AD/PD 2026 - Stock Titan

New Alzheimer’s and Parkinson’s trial data from Annovis headed to AD/PD 2026  Stock Titan

New Alzheimer’s and Parkinson’s trial data from Annovis headed to AD/PD 2026 - Stock Titan

Click here to get full coverage on Insider Purchase: President & CEO of $ANVS Buys 97,561 Shares - quiverquant.com

Insider Purchase: President & CEO of $ANVS Buys 97,561 Shares  quiverquant.com

Insider Purchase: President & CEO of $ANVS Buys 97,561 Shares - quiverquant.com

Click here to get full coverage on Wearables track Parkinson's symptoms in Annovis drug study - Stock Titan

Wearables track Parkinson's symptoms in Annovis drug study  Stock Titan

Wearables track Parkinson's symptoms in Annovis drug study - Stock Titan

Click here to get full coverage on CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan

CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role  Stock Titan

CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan

Click here to get full coverage on Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan

Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS)  Stock Titan

Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan

Click here to get full coverage on Annovis Bio (NYSE: ANVS) to share two CTAD 2025 presentations on buntanetap - Stock Titan

Annovis Bio (NYSE: ANVS) to share two CTAD 2025 presentations on buntanetap  Stock Titan

Annovis Bio (NYSE: ANVS) to share two CTAD 2025 presentations on buntanetap - Stock Titan

Click here to get full coverage on Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan

Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program  Stock Titan

Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan

Click here to get full coverage on Annovis Bio (NYSE: ANVS) sets Jan. 28 update webinar, Q&A - Stock Titan

Annovis Bio (NYSE: ANVS) sets Jan. 28 update webinar, Q&A  Stock Titan

Annovis Bio (NYSE: ANVS) sets Jan. 28 update webinar, Q&A - Stock Titan

Click here to get full coverage on Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat

Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS  MarketBeat

Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat

Click here to get full coverage on AEHR,ANVS,SPT,CRNC,AN,SMTC | stock prices | quote comparison - Yahoo Finance UK

AEHR,ANVS,SPT,CRNC,AN,SMTC | stock prices | quote comparison  Yahoo Finance UK

AEHR,ANVS,SPT,CRNC,AN,SMTC | stock prices | quote comparison - Yahoo Finance UK

Click here to get full coverage on Annovis Bio (NYSE: ANVS) buntanetap cuts tau biomarkers, halts decline in PD - Stock Titan

Annovis Bio (NYSE: ANVS) buntanetap cuts tau biomarkers, halts decline in PD  Stock Titan

Annovis Bio (NYSE: ANVS) buntanetap cuts tau biomarkers, halts decline in PD - Stock Titan

Click here to get full coverage on Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - GlobeNewswire

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study  GlobeNewswire

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - GlobeNewswire

Click here to get full coverage on DSMB clears Annovis Bio (NYSE: ANVS) Phase 3 Alzheimer’s trial to continue - Stock Titan

DSMB clears Annovis Bio (NYSE: ANVS) Phase 3 Alzheimer’s trial to continue  Stock Titan

DSMB clears Annovis Bio (NYSE: ANVS) Phase 3 Alzheimer’s trial to continue - Stock Titan

Click here to get full coverage on Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - GlobeNewswire

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results  GlobeNewswire

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - GlobeNewswire

Click here to get full coverage on Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView

Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO  TradingView

Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView

Click here to get full coverage on Top Insider Makes Bold Multi-Million Dollar Move Into Annovis Bio - TipRanks

Top Insider Makes Bold Multi-Million Dollar Move Into Annovis Bio  TipRanks

Top Insider Makes Bold Multi-Million Dollar Move Into Annovis Bio - TipRanks

Click here to get full coverage on Annovis Bio, Inc. Announces $6 Million Registered Direct Offering of Common Stock - quiverquant.com

Annovis Bio, Inc. Announces $6 Million Registered Direct Offering of Common Stock  quiverquant.com

Annovis Bio, Inc. Announces $6 Million Registered Direct Offering of Common Stock - quiverquant.com

Click here to get full coverage on Should I buy Annovis Bio (ANVS) - zacks.com

Should I buy Annovis Bio (ANVS)  zacks.com

Should I buy Annovis Bio (ANVS) - zacks.com

Click here to get full coverage on NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - GlobeNewswire

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial  GlobeNewswire

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - GlobeNewswire

Click here to get full coverage on Annovis Bio Appoints Mark Guerin as Chief Financial Officer to Support Late-Stage Development of Buntanetap - quiverquant.com

Annovis Bio Appoints Mark Guerin as Chief Financial Officer to Support Late-Stage Development of Buntanetap  quiverquant.com

Annovis Bio Appoints Mark Guerin as Chief Financial Officer to Support Late-Stage Development of Buntanetap - quiverquant.com

Click here to get full coverage on Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease - GlobeNewswire

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease  GlobeNewswire

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease - GlobeNewswire

Click here to get full coverage on Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results - Yahoo Finance

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results  Yahoo Finance

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results - Yahoo Finance

Click here to get full coverage on Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews

Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough?  RTTNews

Keeping Neurodegeneration Top Of Mind: Is Annovis Bio's Pipeline Progress Enough? - RTTNews

Click here to get full coverage on Annovis Bio receives patent for buntanetap in brain infections By Investing.com - Investing.com Australia

Annovis Bio receives patent for buntanetap in brain infections By Investing.com  Investing.com Australia

Annovis Bio receives patent for buntanetap in brain infections By Investing.com - Investing.com Australia

Click here to get full coverage on Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewswire

Annovis to Host Corporate Update Webinar on January 28, 2026  GlobeNewswire

Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewswire

Click here to get full coverage on Annovis Announces $6 Million Registered Direct Offering of Common Stock - Yahoo Finance

Annovis Announces $6 Million Registered Direct Offering of Common Stock  Yahoo Finance

Annovis Announces $6 Million Registered Direct Offering of Common Stock - Yahoo Finance

Click here to get full coverage on Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS) - Benzinga

Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS)  Benzinga

Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS) - Benzinga

Click here to get full coverage on Insider Stock Purchases: November 12, 2025 - quiverquant.com

Insider Stock Purchases: November 12, 2025  quiverquant.com

Insider Stock Purchases: November 12, 2025 - quiverquant.com

Click here to get full coverage on Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView

Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial  TradingView

Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView

Click here to get full coverage on Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - GlobeNewswire

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference  GlobeNewswire

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - GlobeNewswire

Click here to get full coverage on Annovis Bio raises $6 million in registered direct offering - investing.com

Annovis Bio raises $6 million in registered direct offering  investing.com

Annovis Bio raises $6 million in registered direct offering - investing.com

Click here to get full coverage on Annovis Bio director Hoffman buys $159k in shares - investing.com

Annovis Bio director Hoffman buys $159k in shares  investing.com

Annovis Bio director Hoffman buys $159k in shares - investing.com

Click here to get full coverage on Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView

Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials  TradingView

Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView

Click here to get full coverage on Insider Stock Purchases: November 22, 2025 - quiverquant.com

Insider Stock Purchases: November 22, 2025  quiverquant.com

Insider Stock Purchases: November 22, 2025 - quiverquant.com

Click here to get full coverage on Insider Stock Purchases: December 09, 2025 - quiverquant.com

Insider Stock Purchases: December 09, 2025  quiverquant.com

Insider Stock Purchases: December 09, 2025 - quiverquant.com

Click here to get full coverage on Annovis Bio CFO departs, CEO appointed as acting CFO - investing.com

Annovis Bio CFO departs, CEO appointed as acting CFO  investing.com

Annovis Bio CFO departs, CEO appointed as acting CFO - investing.com

Click here to get full coverage on Annovis Bio (ANVS): Alzheimer’s Data, Cash Burn and Why Traders Are Split - AD HOC NEWS

Annovis Bio (ANVS): Alzheimer’s Data, Cash Burn and Why Traders Are Split  AD HOC NEWS

Annovis Bio (ANVS): Alzheimer’s Data, Cash Burn and Why Traders Are Split - AD HOC NEWS

Click here to get full coverage on Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView

Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial  TradingView

Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView

Click here to get full coverage on Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan

Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage  Stock Titan

Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan

Click here to get full coverage on Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease. - Bitget

Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease.  Bitget

Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease. - Bitget

Click here to get full coverage on Annovis Bio raises $3.4 million in registered direct offering - investing.com

Annovis Bio raises $3.4 million in registered direct offering  investing.com

Annovis Bio raises $3.4 million in registered direct offering - investing.com

Click here to get full coverage on Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - investing.com

Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring  investing.com

Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - investing.com

Click here to get full coverage on ANVS Stock Price, News & Analysis | Annovis Bio - Stock Titan

ANVS Stock Price, News & Analysis | Annovis Bio  Stock Titan

ANVS Stock Price, News & Analysis | Annovis Bio - Stock Titan

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Annovis Announces $6 Million Registered Direct Offering Of Common Stock - TradingView

Annovis Announces $6 Million Registered Direct Offering Of Common Stock  TradingView

Annovis Announces $6 Million Registered Direct Offering Of Common Stock - TradingView

Click here to get full coverage on The Truth About Anovis Bio Inc: Is This ‘Brain Booster’ Stock About To Explode Or Fade Out? - AD HOC NEWS

The Truth About Anovis Bio Inc: Is This ‘Brain Booster’ Stock About To Explode Or Fade Out?  AD HOC NEWS

The Truth About Anovis Bio Inc: Is This ‘Brain Booster’ Stock About To Explode Or Fade Out? - AD HOC NEWS

Click here to get full coverage on Annovis Bio’s phase 3 Alzheimer’s trial reaches 25% completion - investing.com

Annovis Bio’s phase 3 Alzheimer’s trial reaches 25% completion  investing.com

Annovis Bio’s phase 3 Alzheimer’s trial reaches 25% completion - investing.com

Click here to get full coverage on Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock - GlobeNewswire

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock  GlobeNewswire

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock - GlobeNewswire

Click here to get full coverage on Annovis Bio Stock Whiplash: Can ANVS Turn Brutal Volatility Into A Breakout? - AD HOC NEWS

Annovis Bio Stock Whiplash: Can ANVS Turn Brutal Volatility Into A Breakout?  AD HOC NEWS

Annovis Bio Stock Whiplash: Can ANVS Turn Brutal Volatility Into A Breakout? - AD HOC NEWS

Click here to get full coverage on Annovis Bio Misses Q1 Earnings Expectations - National Today

Annovis Bio Misses Q1 Earnings Expectations  National Today

Annovis Bio Misses Q1 Earnings Expectations - National Today

Click here to get full coverage on Annovis Bio CFO departs, CEO appointed as acting CFO By Investing.com - Investing.com Australia

Annovis Bio CFO departs, CEO appointed as acting CFO By Investing.com  Investing.com Australia

Annovis Bio CFO departs, CEO appointed as acting CFO By Investing.com - Investing.com Australia

Click here to get full coverage on Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS

Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze?  AD HOC NEWS

Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS

Click here to get full coverage on Annovis Bio’s Stock: Volatile Biotech Bet Faces A Harsh Reality Check - AD HOC NEWS

Annovis Bio’s Stock: Volatile Biotech Bet Faces A Harsh Reality Check  AD HOC NEWS

ANVS

Price Chart

Key Statistics

Technicals

About ANVS

Latest News

ANVS Stock Price and Chart — NYSE:ANVS - TradingView

Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan

Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 713,800 Shares of Stock - MarketBeat

Advanced Charts

Top Gainers

Top Losers